BioSpace News Archive

Portola Pharmaceuticals, Inc.® announced that on February 28, 2020, the Compensation Committee of the Board of Directors approved, effective as of February 28, 2020, a grant to Rajiv Patni of inducement stock options to purchase 125,000 shares of common stock, and awards of 35,000 restricted stock units.

Modern Vascular today announced the growth of its national footprint with the opening of a new facility in Thornton, CO, bringing its treatment of Peripheral Artery Disease (PAD) to Denver area residents.

Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced that it will release fourth quarter and full year 2019 financial results on Monday, March 9, 2020, after the close of markets.

Conformis, Inc. (NASDAQ:CFMS), announced today financial results for the fourth quarter and year ended December 31, 2019.

The Washington Poison Center is pleased to announce the winner of its 14th annual Poison Prevention Poster Contest: Vivian Vuong, a 4th grade student at Shorewood Elementary in Burien, Washington.

Daniel Menichella was invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreak’s response.

Vizient, Inc. recently shared insights on chimeric antigen receptor T-cell data and its implications for patients with cytokine release syndrome, large B-cell cancer, and pediatric and young adult patients with leukemia.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced that it plans to pause the pivotal study of the Omnipod Horizon™ Automated Glucose Control System to correct a software anomaly.

Future-oriented and long-term alliance with Endocyte for the further expansion of targeted radioligand therapy with no-carrier-added Lutetium-177 for prostate cancer patients

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that following a recent change to the Food and Drug Administration’s (FDA) policy towards the coronavirus outbreak, the Company’s coronavirus test kits are available to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) for use according to the FDA guidelines.